SKSandra Obikawa Kyosen

Sandra Obikawa Kyosen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra Obikawa Kyosen has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rare diseases in Brazil: a nationwide analysis of the diagnostic odyssey

    by de Oliveira, Bibiana Mello, Monique Sartori Broch, Carolina Peçaibes, Angélica Piovesana, Claudia Fernandes Lorea, Mariana Lima Scortegagna, Gabriella Zanin Fighera, Isadora Viegas, Laíse Pauletti Barp, et al.

    Background: The diagnostic odyssey of individuals with rare diseases is prolonged and associated with clinical, emotional, and financial burden. In Brazil, data on diagnostic delays and their determinants remain scarce. Objective: This study aims to characterize the diagnostic odyssey of individuals with rare diseases using data from the Brazilian Rare Diseases Network (RARAS). Methods: This descriptive cross-sectional study analyzed ambispective data collected from 2018-2025 across RARAS centers nationwide. Diagnostic odyssey was defined as the time between symptom onset and definitive diagnosis. Prenatal and newborn screening diagnoses were excluded. Sociodemographic, clinical and etiological data were collected through a standardized REDCap-based instrument. Results: Among 18,625 unique participants, 12,048 had confirmed diagnoses and 5,984 met criteria for diagnostic odyssey analysis. The mean diagnostic interval was 6.21 years (± 8.41; median 2.94, IQR 0.80–8.13), indicating substantial heterogeneity. Longer delays were observed in individuals with symptom onset during adolescence. Patients referred during hospital admission experienced shorter diagnostic intervals. Regional differences were significant ( p <0.001), with longer intervals in the Southeast region. Mean time to diagnosis ranged from 2.01 (± 2.89) years (achondroplasia) to 16.40 (± 12.59) years (hereditary angioedema). Patients consulted a mean of 5.32 (± 9.63) physicians and accessed 3.15 (± 4.96) healthcare services before diagnosis. Diagnostic intervals varied by race/ethnicity and etiological category, with longer delays among those with molecular diagnoses, while no association was observed with socioeconomic class. Conclusion: The diagnostic odyssey for rare diseases in Brazil remains prolonged and heterogeneous, reflecting structural disparities, healthcare fragmentation, and diagnostic complexity. These findings suggest that delays are not driven solely by limited access to advanced diagnostics, but also by barriers in early recognition, referral pathways, and care coordination, underscoring the need for integrated strategies across the health system.

  • Open Access

    Diagnostic and Clinical-Epidemiological Insights into Pompe Disease: A Retrospective Analysis at a Reference Center for Inborn Errors of Metabolism

    by Sandra Obikawa Kyosen, Karen Barbosa Müller, Ana Maria Martins, Vania D’ALmeida

    Pompe disease (PD) is characterized by an inborn metabolic error resulting from the deficiency of the enzyme acid alpha-glucosidase, leading to glycogen accumulation within lysosomes. The severity of the disease is related to the age of symptom onset and the time to diagnosis. This study aimed to retrospectively evaluate the clinical and epidemiological profile of patients with suspected PD referred for diagnosis at a reference center for Inborn Errors of Metabolism in Brazil, between 2005 and 2010. Most diagnostic requests came from the Southeast region of Brazil, made by geneticists (29.2%), neurologists (21.3%), and pediatricians (14.4%) for infantile-onset phenotypes, and by pediatric neurologists (31.4%) and geneticists (28.9%) for late-onset phenotypes. Enzyme testing revealed 5.5% of positive cases for PD, of which 38.5% were classified as infantile-onset and 61.5% as late-onset. A high prevalence of muscular abnormalities was observed in all cases, with cardiac manifestations predominating in infantile-onset and neurological and neuromuscular symptoms in late-onset. These findings are relevant for improving early diagnostic and therapeutic strategies. Moreover, the data underscores the importance of multidisciplinary collaboration among medical specialists, in facilitating a more comprehensive and effective approach to managing PD.

  • Open Access

    Análise da mortalidade pediátrica por Epidermólise Bolhosa no Brasil: variações temporais, distribuição geográfica e implicações para políticas de saúde

    by Laura Reis, Larissa Nascimento, Sandra Kyosen

    A Epidermólise Bolhosa hereditária (EB) é uma doença genética rara que causa fragilidade da pele e a formação de bolhas em resposta a traumas mínimos. A condição possui tipos fenotipicamente distintos, EB simples, juncional, distrófica e tipo Kindler, com uma clínica heterogênea, que variam de lesões localizadas a extensas. Pacientes com EB enfrentam complicações, além de desafios emocionais e sociais. O manejo clínico foca no controle das lesões e no alívio da dor, com acompanhamento multiprofissional. O Protocolo Clínico e Diretrizes Terapêuticas (PCDT) de 2021 busca melhorar o tratamento e a qualidade de vida dos pacientes. O objetivo foi identificar os óbitos pediátricos decorrentes da EB no Brasil no período de 1996 a 2022. MÉTODOS: Estudo ecológico descritivo, realizado a partir da pesquisa dos dados de mortalidade do CID-10 Q81, fornecidos pelo DATASUS, para identificar óbitos no Brasil entre 1996 e 2022, considerando regiões geográficas e faixas etárias. A análise foi realizada no Excel® 2019, com análise estatística descritiva. RESULTADOS: Entre 1996 e 2022, ocorreram 1.718.544 óbitos na faixa etária pediátrica, dos quais 175 foram por epidermólise bolhosa (EB), representando 0,0000102% do total. O maior número de óbitos ocorreu entre 1996-2000 (40,57%), seguido por 2001-2005 (31,43%). A partir de 2006, os óbitos diminuíram, com 9,14% registrados entre 2006-2010 e 6,29% entre 2011-2015. As porcentagens mantiveram-se baixas em 2016-2020 (9,14%) e 2021-2022 (3,43%). A região Sudeste teve o maior número de óbitos (46,9%), e a maioria dos óbitos (87,7%) ocorreu em menores de 1 ano. CONCLUSÃO: A EB apresenta alta mortalidade, especialmente em lactentes, e desigualdades no acesso a cuidados. Destaca-se a necessidade de diagnóstico precoce, manejo adequado e políticas públicas, com apoio de organizações como a DEBRA, para melhorar a qualidade de vida dos pacientes.

  • Teaching and training of human resources for genetics and genomics in Brazil

    by Fernanda Teresa de Lima, Maria Angélica de Faria Domingues de Lima, Patrícia Santana Correia, Rachel Sayuri Honjo, Rayana Elias Maia, Sandra Obikawa Kyosen, Débora Gusmão Melo

    This manuscript reviewed the state of the art about the teaching and training of human resources for genetics and genomics in Brazil. We presented the national scenario of teaching genetics in medical undergraduate and other health courses. We discussed the training of medical geneticists through medical residency and addressed the training in genetics of physicians from specialties other than genetics. We examined the training of health professionals specializing in genetics through lato sensu and stricto sensu postgraduate programs and presented the proposals for multi-professional residency in genetic counseling and genetics and genomics that are currently the subject of discussion in the country. Finally, we highlighted the importance of training primary health care professionals concerning genetics and genomics for the effective establishment of a line of care for individuals with genetic disorders in the Brazilian Unified Health System. Therefore, we provided a thorough overview of how genetics is (or is not) incorporated into professional training in a comprehensive public healthcare system such as the Brazilian.


  • ÓXIDO NÍTRICO COMO TRATAMENTO DA HIPERTENSÃO PULMONAR EM NEONATOS

    by Rita de Cássia Lompa Juelg, Paula Myllena, Patricia Ikeda, Verônica Campos Resende, Sandra Obikawa Kyosen

    Introdução: A hipertensão pulmonar em recém-nascido é um problema comum com característica e mortalidade significativas e limita a quantidade de sangue que vai para os pulmões. O uso de óxido nítrico (NO) é um vasodilatador que relaxa o músculo liso e eleva os níveis de oxigênio no sangue, sendo uma opção de tratamento para essa patologia. É necessário analisar as condições dessa utilização. Foi observado que o tratamento não inclui pacientes com hérnia diafragmática bem como reduz o uso de oxigenação por membrana extracorporal (ECMO) em pacientes que fizeram o tratamento. Objetivo: Esse artigo de revisão objetiva analisar a viabilidade de conduzir o uso do óxido nítrico no tratamento da hipertensão pulmonar em neonatos, avaliando os resultados, os efeitos e o perfil de segurança. Método: Este artigo é uma revisão bibliográfica de caráter analítico. Foi utilizado como base de dados para pesquisa os periódicos indexados no PubMed e os descritores pesquisados no DeCS para refinar a busca foram: Nitric Oxide; pulmonary hypertension; neonates. Os critérios de inclusão utilizados foram artigos que dissertam sobre o uso do NO como tratamento da hipertensão pulmonar em neonatos, publicados entre 2011 e 2021. Os critérios de exclusão foram por não abranger completamente o assunto proposto. Conforme esses critérios, foram selecionados 9 artigos para a realização dessa redação. Desenvolvimento: A utilização do óxido nítrico não causa sequelas no neurodesenvolvimento, mas dosagem baixas podem desempenhar toxicidade celular. Além disso, o NO reduz a necessidade de uso de ECMO, visto que essa possui muitas complicações e é uma vantagem no tratamento não a utilizar. As complicações incluem: hipotensão, metemoglobinemia, vasoespasmo pulmonar e piora da insuficiência cardíaca. O uso do NO também reduz os gastos hospitalares, tanto evitando o uso de ECMO, quanto diminuindo o tempo de internação do paciente. Conclusão: Em virtude do que foi mencionado, a inalação de óxido nítrico pode melhorar significativamente a oxigenação e evitar a progressão para gravidade do quadro clínico, sendo reconhecido como terapia eficaz para bebês a termo e a curto prazo com insuficiência respiratória hipóxica, com exceção daqueles com hérnia diafragmática. Ao atuar como um vasodilatador endógeno, ele encurta o tempo de tratamento, já que aumenta o suprimento de oxigênio e reduz a pressão da artéria pulmonar. Palavras-chave: óxido nítrico; hipertensão pulmonar; recém-nascido.

  • Open Access

    A New Mutation in IDS Gene Causing Hunter Syndrome: A Case Report

    by Caio Perez Gomes, Maryana Mara Marins, Fabiana Louise Motta, Sandra Obikawa Kyosen, Marco Antonio Curiati, Vânia D’almeida, Ana Maria Martins, João Bosco Pesquero

    Rationale: Mucopolysaccharidosis type II (Hunter syndrome) is an X-linked multisystem disorder, caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S). The clinical manifestations of this disease are severe skeletal deformities, airway obstruction, cardiomyopathy, and neurologic deterioration. Patient: The patient was 5 years and 6 months boy, with developmental delay, hearing loss, hepatosplenomegaly, and skeletal dysplasia. He was diagnosed with mucopolysaccharidosis type II based on clinical manifestations, biochemical and genetic analysis. Outcomes: The patient carries a new mutation (c.879-1210_1007-218del) in hemizygosis in the IDS gene, which was defined as pathogenic according to the 2015 American College of Medical Genetics and Genomics-Association for Molecular Pathology guidelines and as responsible for the mucopolysaccharidosis type II phenotype in the patient.


  • Open Access

    CASE SERIES OF PATIENTS UNDER BIWEEKLY TREATMENT WITH LARONIDASE: A REPORT OF A SINGLE CENTER EXPERIENCE

    by Sandra Obikawa Kyosen, Leny Toma, Helena Bonciani Nader, Marion Coting Braga, Vanessa Gonçalves Pereira, Sueli Canossa, João Bosco Pesquero, Vânia D’aLmeida, Ana Maria Martins

    Objective: To report the stabilization of urinary glycosaminoglicans (GAG) excretion and clinical improvements in patients with mucopolysaccharidosis type I (MPS I) under an alternative dose regimen of laronidase of 1.2 mg/kg every other week. Methods: We participated in a dose-optimization trial for laronidase in MPS-I patients using four alternative regimens: 0.58 mg/kg every week, 1.2 mg/kg every two weeks, 1.2 mg/kg every week and 1.8 mg/kg every other week (EOW). After the trial ended, the patients resumed the recommended dose and regimen of 0.58 mg/kg every week. Under this regimen, some patients presented difficulties in venous access and were unable to commute weekly to the treatment center. Therefore, we used an alternative regimen that consisted of 1.2 mg/kg EOW in eight patients. A retrospective study of medical records of MPS-I patients who underwent both enzyme replacement therapy (ERT) regimens, of 0.58 mg/kg every week and 1.2 mg/kg EOW, was done. Results: Patients remained clinically stable under the alternative regimen, did not present elevation of urinary GAG nor any adverse event. Conclusions: The switch of dose regimen to 1.2 mg/kg EOW of laronidase was safe, and did not cause any clinical worsening in patients who had been previously under standard dose ERT.

  • Endoscopic Findings in Lysosomal Acid Lipase Deficiency

    by Sandra Obikawa Kyosen, Stephan Geocze, Marcelo Hideki Yamamoto, Ana Maria Martins


  • Open Access

    Oxidative stress assessment by glutathione peroxidase activity and glutathione levels in response to selenium supplementation in patients with Mucopolysaccharidosis I, II and VI

    by José Araújo de Oliveira-Silva, Joyce Umbelino Pinto Yamamoto, Renata Bernardes de Oliveira, Vaneisse Cristina Lima Monteiro, Beatriz Jurkiewcz Frangipani, Sandra Obikawa Kyosen, Ana Maria Martins, Vânia D’almeida

    We assessed levels of plasma selenium (Se), selenoproteins and their change after Se supplementation in patients with mucopolysaccharidosis (MPS) types I, II and VI. This was done in a retrospective study of the medical records of 30 patients with MPS I (n=13), MPS II (n=9) and MPS VI (n=8) who were being treated with enzyme replacement therapy. As part of routine nutritional monitoring, Se levels were measured, revealing that 28 patients (93.3%) had values below the normal range. Therefore, they received supplementation for 12 months, and Se was measured after 6 and 12 months. Glutathione peroxidase (GPx) activity, total glutathione (GSHt), oxidized glutathione (GSSG) and reduced glutathione (GSH) were measured at baseline and 6 months after Se supplementation. The mean GSHt at baseline was 7.90 ± 2.36 μmol/g Hb, and after Se supplementation it was 5.76 ± 1.13 μmol/g Hb; GSH/GSSG was 2.3 ± 1.16 at baseline and 0.58 ± 0.38 after supplementation. GPx activity was 16.46 ± 3.31 U/g Hb at baseline and 4.53 ± 4.92 U/g Hb after Se supplementation. The difference was shown to be statistically significant by paired t-test. In conclusion, our study demonstrated that oxidative stress parameters were altered by Se supplementation in patients with MPS I, II and VI who were previously deficient in Se.